SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

Cancers harboring spliceosome mutations are highly sensitive to additional perturbations on the spliceosome that leads to the development of onco-therapeutics targeting the spliceosome and opens novel opportunities for managing aggressive tumors lacking effective treatment options such as triple-negative breast cancers.